The American Journal of Medicine
Volume 123, Issue 2 , Pages 101-102 , February 2010

Aspirin for the Primary Prevention of Stroke and Myocardial Infarction: Ineffective or Wrong Dose?

References 

  1. Soni A. Aspirin use among the Adult U.S. noninstitutionalized population, with and without indicators of heart disease, 2005. Agency for Healthcare Research and Quality; July, 2007;
  2. Dalen JE. Aspirin to prevent heart attack and stroke: what's the right dose?. Am J Med. 2006;119:198–202
  3. Steering Committee of the Physicians' Health Study Research Group. Final report of the aspirin component of the ongoing physicians' health study. N Engl J Med. 1989;321:129–135
  4. Becker RC, Meade TW, Berger PB, et al. The primary and secondary prevention of coronary artery disease. Chest. 2008;133:776S–814S
  5. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. J Am Coll Cardiol. 2008;52:1502–1517
  6. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. preventive services task force recommendation statement. Ann Intern Med. 2009;150:396–404
  7. American Heart Association. http://www.americanheart.org/presenter.jhtml?identifier=4704Accessed October 28, 2009
  8. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes. JAMA. 2008;300:2134–2141
  9. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840
  10. Fowkes G. Aspirin for asymptomatic atherosclerosis trial. Presented at European Society of Cardiology 2009 Congress, August 30, 2009, Barcelona, Spain.
  11. Hiatt WR. Aspirin for prevention of cardiovascular events. BMJ. 2008;337:a1806
  12. Antithrombotic Trialists (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860
  13. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Lancet. 1988;296:313–316
  14. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet. 1998;351:233–241
  15. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet. 1998;351:1755–1762
  16. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet. 2001;357:89–95
  17. Ridker PM, Cook NR, Min Lee I, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;353:1293–1304

 Funding: None.

 Conflict of Interest: None.

 Authorship: Dr. Dalen is the sole author of this manuscript and had full access to the data.

PII: S0002-9343(09)00976-0

doi: 10.1016/j.amjmed.2009.11.001

The American Journal of Medicine
Volume 123, Issue 2 , Pages 101-102 , February 2010

Article Tools